Chaim Indig: Look, obviously, we’ve acquired some things where we thought the capabilities made more sense for us to acquire than to build. We’ve done that in the past. We believe that we want to be both good stewards of capital but also, we want to buy really great things, not just good deals, right? And I know some people believe valuations have sort of come in line on the private side. I think that there’s still a lot of expectation resetting that needs to happen there, probably more than has happened to date, Stephanie. But look, we looked at things. We will continue to look at things. Frankly, as an organization, we also feel pretty good that we’re good at building things and we’re good at getting clients, get our software and to use our network.
And we deliver phenomenal value. So the things that we care about are things that drive phenomenal value to our clients, and we’ll just keep doing that. And if there’s things that add value to the clients and add great returns to our shareholders, then we’ll look at them. But I don’t know, we’ll be thoughtful.
Balaji Gandhi: And it gets back to my earlier point around just capital allocation returns because I think we’ve done some acquisitions and it’s just sort of lined up the right way for us. But we’ll have to see. I mean you’ll have to let us know how quickly things change.
Chaim Indig: There’s a lot of traffic there.
Stephanie Davis: Hope we see a lot of change there. Thanks, guys.
Operator: And from Canaccord Genuity, we’ll hear next from Richard Close.
Richard Close: Great. Thanks for the question. Congratulations to both of you. So maybe diving in on life sciences, a little bit more into Annie’s question. Just maybe if you could provide some details on the growth there in terms of maybe getting greater wallet share from existing customers versus new pharma clients coming onboard to the platform.
Chaim Indig: Look, it’s been a couple of things. It’s been greater wallet share in the brands we work with. It’s been more brands at the pharmaceutical customers and clients and life sciences companies that we previously worked with, so expanding our footprint. And then it’s winning new clients that we haven’t worked with before or we’ve worked with, and they’ve been at a previous company or the agency that we work with has had great success with us with some clients and now they recommend us for other clients. So I think a lot of our growth has been driven by just delivery. And it’s a pretty small world. So doing what you say you’re going to do and doing it really well over and over again has been a big part of our success and treating clients really well. And we try really hard. The team has been great at it. It’s been all of the above. Balaji is going to pull up a stat, he’s got a good stat here.
Balaji Gandhi: Yes. Richard, from time-to-time, we do update some of this stuff in our deck. So I would look at it. I’m looking at Slide 9 of our investor deck. And we work with more than 80 brands. And if you look back, that number was about in the 40s when we went public 2019. And the last time we updated this deck, it was over 70 brands.
Chaim Indig: So the answer is more.
Balaji Gandhi: More.
Richard Close: Okay. Chaim, maybe just as you’re out talking to potential clients, even existing clients and getting feedback from your sales team, I guess any perspectives you can share with us in terms of like what’s the mindset of health care providers right now? Has anything meaningfully changed maybe over the last year? What are the pain points, is it the same? Any update there would be helpful.
